Clinical pipeline promises effective 2nd-generation COVID-19 vaccines
Despite the small number of COVID-19 vaccines that have been granted emergency use authorizations by the U.S. Food and Drug Administration to date, many biopharmaceutical companies are continuing to push new vaccine candidates toward regulatory approval. The slow rollout of approved vaccines has created the need for second-generation products with the potential to accelerate the world's return to something approaching normalcy. Read More
Merck to acquire Pandion for $1.85B
Merck has announced that it will acquire Pandion Therapeutics for $1.85 billion. Read More
Debiopharm, Genome & Company collaborate on antibody-drug conjugates
Debiopharm and Genome & Company announced a plan to collaborate on developing antibody-drug conjugate oncology therapies. Read More
Jaguar Gene Therapy launches, targeting rare genetic diseases
Jaguar Gene Therapy has launched after being in stealth mode with the goal of accelerating the development, manufacturing, and commercialization of novel gene therapy treatments for patients with severe genetic diseases. Read More
Altimmune begins trial of nasal COVID-19 vaccine
Altimmune has begun enrollment in a phase I clinical trial of AdCOVID, a single-dose, intranasal COVID-19 vaccine candidate. Read More
Seven Bridges to provide scRNAseq data management for Pfizer
Bioinformatics provider Seven Bridges has been selected by Pfizer to provide data management services for Pfizer's single-cell RNA sequencing (scRNAseq) data. Read More
Yokogawa leverages ICQ to bring bioreactors to U.S.
Yokogawa Electric has entered into a partnership with Integrated Commissioning and Qualification Consultants (ICQ) in which ICQ will provide consulting and engineering services for the installation, maintenance, qualification, and support of Yokogawa's bioreactor systems and related products in the U.S. Read More
Simulations Plus, Univ. of Pittsburgh partner to evaluate large-molecule drugs
Medical simulation software company Simulations Plus and the University of Pittsburgh Drug Discovery Institute have jointly received a phase I grant from the U.S. National Institutes of Health-funded Small Business Innovation Research grant to support their large-molecule safety collaboration. Read More
Oncolytics reports results of immuno-oncolytic virus with CAR T therapy
Oncolytics Biotech is reporting new data from a preclinical study where pelareorep, its proprietary immuno-oncolytic virus and chimeric antigen receptor (CAR) T-cell combination therapy for solid tumors, vastly improved outcomes compared to the use of an oncolytic vesicular stomatitis virus to weaken tumors. Read More
Phlow, USP to establish continuous manufacturing validation lab
Phlow and United States Pharmacopeia (USP) have formed a strategic alliance to develop a new laboratory to certify and validate continuous pharmaceutical manufacturing processes. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter